Breaking the Amendment Cycle: How Agentic AI Enables Smarter Clinical Trial Design and Operations
Faster trials are not a vanity metric. They reflect an undeniable need: getting safe therapies…
Breaking the Amendment Cycle: How Agentic AI Enables Smarter Clinical Trial Design and Operations
Faster trials are not a vanity metric. They reflect an undeniable need: getting safe therapies to patients sooner. The post Breaking the Amendment Cycle: How Agentic AI Enables Smarter Clinical Trial Design and Operations appeared first on MedCity News.
“We’re Sorry, That’s the Policy”: How a Medicare Advantage Runaround Nearly Cost a Senior His Sight
By FRANK LEAHY On a gray February morning, I sat in my office in Inverness, in rural northern California, with the phone pressed to my ear, jotting down notes and Humana reference numbers. Across the table, my new friend Rick, 77, waited anxiously, struggling to follow the conversation. Nearly deaf and now partially blind, Rick…
Healthcare Moves: A Monthly Summary of Hires, Exits and Layoffs
August has seen a slew of executive hires, exits and layoffs across the healthcare industry. For instance, Humana, Merck and Mayo Clinic named new executives. There were also layoffs at organizations including MaineHealth, Cellares and Sharp HealthCare. The post Healthcare Moves: A Monthly Summary of Hires, Exits and Layoffs appeared first on MedCity News.
MedCity FemFwd: How Midwives Can Support the Maternal Health Crisis
In this episode, we’re joined by Amanda Shafton, practicing CNM and national director of midwifery at Ob Hospitalist Group. We discuss the benefits of physician/midwifery collaboration and how midwives can improve maternal health outcomes. The post MedCity FemFwd: How Midwives Can Support the Maternal Health Crisis appeared first on MedCity News.
4 Notable Health Tech Funding Announcements in August
Health tech companies made several major funding announcements in August. Here is a list of some of the biggest funding rounds. The post 4 Notable Health Tech Funding Announcements in August appeared first on MedCity News.
First-in-Class Takeda, Protagonist Drug Lands FDA Approval in Rare Blood Disorder
Takeda Pharmaceutical’s Mimrylo is now approved for treating polycythemia vera, a rare blood cancer with limited therapeutic options. Originally developed by Protagonist Therapeutics, the engineered peptide gives Takeda a drug with blockbuster sales potential as the pharma company’s top overall product faces patent expirations. The post First-in-Class Takeda, Protagonist Drug Lands FDA Approval in Rare…
AI Won’t Transform Health Systems, CEOs Will — 6 Principles to Drive the Transformation
If AI is not one of the CEO’s top two or three priorities, the organization will produce pilots and slide decks while better-mobilized peers pull ahead and the institution’s ability to fulfill its mission erodes The post AI Won’t Transform Health Systems, CEOs Will — 6 Principles to Drive the Transformation appeared first on MedCity…
Big Bucks, No Whammies: Patient Access Was Never the Finish Line
By STEPHEN FARBER If you grew up in the 1980s, you probably remember Press Your Luck. Contestants stood in front of a flashing game board chanting, “Big bucks… no Whammies… STOP!” hoping the next square held cash instead of the mischievous cartoon character that erased everything they had won. For years, assembling your own medical…
Hospitals Are All In on AI, but Testing and Oversight Haven’t Caught Up
A new report found that while more than 90% of health systems have deployed third-party AI tools, less than half have the infrastructure to properly test and validate them before they become embedded in patient care. The post Hospitals Are All In on AI, but Testing and Oversight Haven’t Caught Up appeared first on MedCity…
SK Bio Broadens U.S. Prospects, Licensing Late-Stage Epilepsy Drug From Biohaven
Biohaven is outlicensing to SK Biopharmaceuticals global rights to opakalim, a Kv7-targeting small molecule in pivotal clinical testing for epilepsy. Biohaven gets non-dilutive financing for its pipeline while SK Bio gains another asset to potentially commercialize in the U.S. The post SK Bio Broadens U.S. Prospects, Licensing Late-Stage Epilepsy Drug From Biohaven appeared first on…
